Pipeline – research and development
Novo Nordisk’s research and development efforts focus on offering superior therapies that help save people’s lives or improve their quality of life.
In diabetes care the aim is to maintain our position as world leader.
In biopharmaceuticals the aim is to expand the franchise within haemostasis and growth hormone therapy, and to build a presence in inflammation and oncology.
Our strategy is to address unmet medical needs by leveraging the company’s core capabilities within diabetes research, protein delivery and therapeutic proteins.
Download a PDF with an overview of the Novo Nordisk pipeline.
The Novo Nordisk R&D pipeline is updated quarterly at novonordisk.com/investors.
Pipeline in brief
A pipeline is a portfolio of pharmaceutical products currently being developed. Many pharmaceutical compounds take 10–15 years to develop. The pipeline provides an overview of the progress of the compounds in the later stages of development.
Phase 1
Studies in a small group of healthy volunteers, usually between 10 and 100, to test a new drug for best dosage and potential side effects.
Phase 2
Testing a drug’s known dose and side effects in a larger group of volunteers to learn of side effects, the body’s use of the drug and its effect on the condition.
Phase 3
Studies in large groups of volunteers to compare the new drug with a commonly used drug for both safety and efficacy.
Filed
A New Drug Application is submitted for review by various government regulatory agencies.
This page has been assessed by PricewaterhouseCoopers as part of its assessment of Novo Nordisk’s statement that it reports ‘in accordance’ with GRI. Please refer to Audit and assurance for a full description of the nature of assurance offered.
